Cyclin-dependent kinase 6

Cell division protein kinase 6 (CDK6) is an is_associated_with::enzyme encoded by the CDK6 is_associated_with::gene. It is regulated by is_associated_with::cyclins, more specifically by is_associated_with::Cyclin D proteins and is_associated_with::Cyclin-dependent kinase inhibitor proteins. The protein encoded by this gene is a member of the is_associated_with::cyclin-dependent kinase, (CDK) family, which includes is_associated_with::CDK4. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of is_associated_with::cell cycle progression in the point of regulation named R or is_associated_with::restriction point.

This kinase is a catalytic subunit of the protein kinase complex, important for the G1 phase progression and G1/S transition of the cell cycle and the complex is composed also by an activating sub-unit; the cyclin D. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor is_associated_with::Retinoblastoma protein making CDK6 an important protein in is_associated_with::cancer development.

Structure
The CDK6 is_associated_with::gene is conserved in is_associated_with::eukaryotes, including the is_associated_with::budding yeast and the is_associated_with::nematode is_associated_with::Caenorhabditis elegans. The CDK6 gene is located in the chromosome 7 in humans, it is encoded by 231,706 base pairs and is translated to a 326 amino acid protein with a kinase function. The gene is over expressed in cancers like is_associated_with::lymphoma, is_associated_with::leukemia, is_associated_with::medulloblastoma and is_associated_with::melanoma associated with chromosomal rearrangements. The CDK6 protein contains a catalytic core composed of a serine/threonine domain. This protein also contains an ATP-binding pocket, inhibitory and activating phosphorylation sites, a PSTAIRE-like cyclin-binding domain and an activating T-loop motif. After binding the Cyclin in the PSTAIRE helix, the protein changes its conformational structure to expose the phosphorylation motif. The protein can be found in the cytoplasm and the nucleus, however most of the active complexes are found in the nucleus of proliferating cells.

Cell cycle
In 1994, Matthew Meyerson and Ed Harlow investigated the product of a close is_associated_with::analogous gene of CDK4. This gene, identified as PLSTIRE was translated into a protein that interacted with the cyclins CD1, CD2 and CD3 (same as CDK4), but that was different from CDK4; the protein was then renamed CDK6 for simplicity. In mammalian cells, cell cycle is activated by CDK6 in the early G1 phase through interactions with cyclins D1, D2 and D3. There are many changes in gene expression that are regulated through this enzymes. After the complex is formed, the C-CDK6 enzymatic complex phosphorylates the protein pRb. After its phosphorylation, pRb releases its binding partner is_associated_with::E2F, a transcriptional activator, which in turns activate DNA replication. The CDK6 complex ensures a point of switch to commit to division responding to external signals, like is_associated_with::mitogens and is_associated_with::growth factors.

CDK6 is involved in a positive feedback loop that activates transcription factors through a reaction cascade. Importantly, these C-DCK complexes act as a kinase, phosphorylating and inactivating the protein of Rb and p-Rb related “pocket proteins” p107 and p130. While doing this, the CDK6 in conjunction with CDK4, act as a switch signal that first appears in G1, directing the cell towards S phase of the cell cycle.

CDK6 is important for the control of G1 to S phase transition. However, in recent years, new evidence proved that the presence of CDK6 is not essential for proliferation in every cell type, the cell cycle has a complex circuitry of regulation and the role of CDK6 might be more important in certain cell types than in others, where CDK4 or is_associated_with::CDK2 can act as protein kinases compensating its role.

Cellular development
In mutant is_associated_with::Knockout mice of CDK6, the hematopoietic function is impaired, regardless of otherwise organism normal development. This might hint additional roles of CDK6 in the development of blood components. There are additional functions of CDK6 not associated with its kinase activity. For example, CDK6 is involved in the differentiation of T cells, acting as an inhibitor of differentiation. Even though CDK6 and CDK4 share 71% amino acid identity, this role in differentiation is unique to CDK6. CDK6 has also been found to be important in the development of other cell lines, for example, CDK6 has a role in the alteration of the morphology of is_associated_with::astrocytes and in the development of other stem cells.

DNA protection
CDK6 differs from CDK4 in other important roles. For example, CDK6 plays a role in the accumulation of the is_associated_with::apoptosis proteins is_associated_with::p53 and p130, this accumulation avoids cells from entering cell division if there is DNA damage, activating pro- apoptotic pathways.

Metabolic homeostasis
Studies in the metabolic control of cells have revealed yet another role of CDK6. This new role is associated with the balance of the oxidative and non-oxidative branches of the pentose pathway in cells. This pathway is a known route altered in cancer cells, when there is an aberrant overexpression of CDK6 and CDK4. The overepression of these proteins provides the cancer cells with a new hallmark capability of cancer; the deregulation of the cell metabolism.

Centrosome stability
In 2013 researches discovered yet another additional role of CDK6. There is evidence that CDK6 associates with the is_associated_with::centrosome and controls organized division and cell cycle phases in neuron production. When the CDK6 gene is mutated in these developing lines, the centrosomes are not properly divided, this could lead to division problems such as is_associated_with::aneuploidy, which in turns leads to health issues like primary is_associated_with::microcephaly.

Mechanisms of regulation
CDK6 is positively regulated primarily by its union to the D cyclins D1,D2 and D3. If this subunit of the complex is not available, CDK6 is not active or available to phosphorylate the pRb substrate. An additional positive activator needed by CDK6 is the phosphorylation in a conserved threonine residue located in 177 position, this phosphorylation is done by the cdk-activating kinases, CAK. Additionally, CDK6 can be phosphorylated and activated by the is_associated_with::Kaposi's sarcoma-associated herpes virus, stimulating the CDK6 over activation and uncontrolled cell proliferation.

CDK6 is negatively regulated by binding to certain inhibitors that can be classified in two groups; CKIs or CIP/KIP family members like the protein p21 and p27 act blocking and inhibiting the assembled C-CDKs binding complex enzymes in their catalytic domain.

Furthermore, inhibitors of the INK4 family members like p15, p16, p18 and p19 inhibit the is_associated_with::monomer of CDK6, preventing the complex formation.

Clinical relevance
CDK6 is a protein kinase activating cell proliferation, it is involved in an important point of restriction in the cell cycle. For this reason, CDK6 and other regulators of the G1 phase of the cell cycle are known to be unbalanced in more than 80-90% of tumors. In cervical cancer cells, CDK6 function has been shown to be altered indirectly by the p16 inhibitor. CDK6 is also overexpressed in tumors that exhibit is_associated_with::drug resistance, for example is_associated_with::glioma malignancies exhibit resistance to is_associated_with::chemotherapy using is_associated_with::Temozolomide (TMZ) when they have a mutation overexpressing CDK6. Likewise, the overexpression of CDK6 is also associated with resistance to is_associated_with::hormone therapy using the anti oestrogen Fluvestrant in is_associated_with::breast cancer.

Cancer
Loss of normal cell cycle control is the first step to developing different is_associated_with::hallmarks of cancer; alterations of CDK6 can directly or indirectly affect the following hallmarks; disregulated cell cellular energetics, sustaining of proliferative signaling, evading growth suppressors and inducing is_associated_with::angiogenesis, for example, deregulation of CDK6 has been shown to be important in lymphoid malignancies by increasing angiogenesis, a hallmark of cancer. These features are reached through upregulation of CDK6 due to chromosome alterations or epigenetic dysregulations. Additionally, CDK6 might be altered through genomic instability, a mechanism of downregulation of is_associated_with::tumor suppressor genes; this represents another evolving hallmark of cancer.

Medulloblastoma
Medulloblastoma is the most common cause of brain cancer in children. About a third of these cancers have upregulated CDK6, representing a marker for poor prognosis for this disease. Since it is so common for these cells to have alterations in CDK6, researchers are seeking for ways to downregulate CDK6 expression acting specifically in those cell lines. The is_associated_with::MicroRNA (miR) -124 has successfully controlled cancer progression in an in-vitro setting for is_associated_with::medulloblastoma and is_associated_with::glioblastoma cells. Furthermore, researchers have found that it successfully reduces the growth of xenograft tumors in rat models.

As a drug target
The direct targeting of CDK6 and CDK4 should be used with caution in the treatment of cancer, the reason why is because these enzymes are important for the cell cycle of normal cells we well. Furthermore, small molecules targeting these proteins might increase drug resistance events. However, these kinases have been shown to be useful as coadjuvants in breast cancer chemotherapy. Another indirect mechanism for the control of CDK6 expression, is the use of a mutated D-cyclin that binds with high affinity to CDK6, but does not induce its kinase activity. this mechanism was studied in the development of mammary is_associated_with::tumorigenesis in rat cells, however, the clinical effects have not yet been shown in human patients. As of 2014, different drugs to target these type of kinases have been developed, however none of those have been yet approved for the treatment of human cancers by the is_associated_with::FDA. Inhibitors of CDK6 have shown the disadvantage of not being specific in the union to the CDK6, and as a consequence they might act inhibiting other CDKs that are crucial in other tissues and at other points of cell cycle. The compound PD-0332991, is currently under more than 20 clinical trials acting either as single agent or as coadjuvant of other therapies in clinical trial phase I-III showing promising results in the control of breast cancer in-vitro.

Interactions
Cyclin-dependent kinase 6 interacts with:


 * is_associated_with::CDKN2C,
 * is_associated_with::Cyclin D1,
 * is_associated_with::Cyclin D3,
 * P16,
 * is_associated_with::PPM1B, and
 * is_associated_with::PPP2CA.